Dr Brian Hill discusses the potential use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma (MCL) and reviews emerging treatment options for patients with MCL.
Early MRD Guides Therapy in Mantle Cell Lymphoma
In an interview with Targeted Oncology, Julie Chang, MD, discussed the minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma and the key findings from the trial.
Read More
Precision Medicine Implemented in the Community Oncology Setting
Technology plays a pivotal role in enhancing precision medicine within cancer care.
What Is High-Risk Mantle Cell Lymphoma, and How Should We Treat It?
Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.
Liso-cel Appears Effective in High-Risk Patients With MCL
Findings suggest that liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features, who have limited treatment options.
Key Updates in Lower-Risk MDS
In the fifth article of this series, Yazan Madanat, MD, reviews recent updates presented at the 2023 ASH Annual Meeting and discusses the evolving treatment landscape.
SYMPATICO Trial of Ibrutinib Plus Venetoclax Boosts PFS in MCL
Matthew Matasar, MD, discussed the rationale and findings of the doublet consisting of ibrutinib and venetoclax for the treatment of mantle cell lymphoma.